Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1012946 | 0.82 | ALDH1A1 (0.33) | ALDH1A1MAPK14KDM4EMAPTBLM | |
| SCHEMBL1012674 | 0.82 | BRD4 (0.33) | ALDH1A1KDM4EMAPTBLM | |
| SCHEMBL17796648 | 0.82 | CYP1A2 (0.38) | ALDH1A1KDM4EMAPTBLMKDR | |
| SCHEMBL1083433 | 0.79 | KDM4E (0.31) | ALDH1A1KDM4EMAPTBLM | |
| SCHEMBL2676735 | 0.79 | MAPK14 (0.37) | ALDH1A1MAPK14KDM4EMAPTBLM | |
| SCHEMBL24410810 | 0.79 | KDM4E (0.31) | ALDH1A1KDM4EMAPTBLM | |
| SCHEMBL9713142 | 0.79 | KDM4E (0.31) | ALDH1A1KDM4EMAPTBLMCNR2 | |
| SCHEMBL16174443 | 0.77 | ALDH1A1 (0.30) | ALDH1A1KDM4EMAPTBLMKDR | |
| SCHEMBL1013262 | 0.77 | CNR2 (0.30) | ALDH1A1KDM4EMAPTBLMCNR2 | |
| SCHEMBL1012771 | 0.77 | CNR2 (0.37) | ALDH1A1KDM4EMAPTBLMCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | claimed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | claimed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | claimed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | claimed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | claimed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | claimed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | claimed |
| WO-2015082357-A1 | S1P3 ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2015-06-11 | — | — | WO | claimed |
| EP-2878339-A1 | SIP3 antagonists | Siena Biotech S.p.A. (IT) | 2015-06-03 | — | — | EP | claimed |
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | claimed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-8173638-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-08 | — | — | US | claimed |
| EP-2398771-A2 | HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-12-28 | — | — | EP | claimed |
| WO-2010096371-A2 | HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | WO | claimed |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | US | claimed |
| EP-2074084-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2009-07-01 | — | — | EP | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
| WO-2008064054-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | claimed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | claimed |
| WO-2008039645-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | CNR2, CNR1, OPRL1 | ALDH1A1 2404/4885HSD17B10 4238/4885MAPK14 1329/4885 |
| US-20100009964-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 1695/4885HSD17B10 1708/4885MAPK14 1110/4885 |
| US-20180201582-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885HSD17B10 2803/4885MAPK14 3273/4885 |
| US-20160297762-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885HSD17B10 2803/4885MAPK14 3273/4885 |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | ALDH1A1 1759/4885HSD17B10 2511/4885MAPK14 767/4885 |
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885HSD17B10 2803/4885MAPK14 3273/4885 |
| US-20200157052-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | ALDH1A1 2988/4885HSD17B10 2803/4885MAPK14 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.